Polphamara: First subjects in ph III study with PB006 (proposed Biosimilar to Natalizumab) have been randomized
Our phase III clinical trial (PB006-03-01) entered into the stage when first patients were treated with study medication.
This study study is conducted in 7 countries in and outside Europe including Poland. First participants were included in the study at the clinical site in Katowice (Poland).
The study, managed by Hendrik Wessels, Polpharma Biologics Clinical Development team, led by Karsten Roth, Director Clinical Research & Development, is an essential part of the development program for the proposed Biosimilar to Natalizumab.